The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key ...
Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...
Vessel density in the deep capillary plexus reflects disease activity and structural involvement in thyroid eye disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback